The Efficacy and Safety of Brain-targeting Immune Cells (EGFRvIII-CAR T Cells) in Treating Patients With Leptomeningeal Disease From Glioblastoma. Administering Patients EGFRvIII -CAR T Cells May Help to Recognize and Destroy Brain Tumor Cells in Patients

Inclusion Criteria:

• Participant has been treated for leptomeningeal metastases after intrathecalchemotherapy and/or radiation OR refuses to undergo additional radiation and/orintrathecal chemotherapy
• Participant must have a Karnofsky performance status (KPS) >= 60
• Participant must have a life expectancy of >= 2 months
• Women of child-bearing potential must have negative serum pregnancy test and agree touse a reliable form of birth control prior to study entry and for at least two monthsfollowing study treatment. Male research participants must agree to use a reliableform of birth control and not donate sperm during the study and for at least twomonths following study treatment
• Participant has a histologically confirmed EGFRvII+ (epidermal growth factor receptor)tumor expression by immunohistochemistry (IHC) at the initial tumor presentation orrecurrent disease (H-score >= 50)
• Participant or legal guardian must have the ability to understand and the willingnessto sign a written informed consent

Exclusion Criteria:

• Research participant requires supplemental oxygen to keep saturation greater than 95%
• Research participant requires dialysis
• Research participant has uncontrolled seizure activity and/or clinically evidentprogressive encephalopathy
• Failure of research participant or legal guardian to understand the basic elements ofthe protocol and/or the risks/benefits of participating in the study.
• Participant is unwilling to stop treatment with chemotherapy or endocrine therapyand/or radiation one week prior and during the first 4 cycles of the study
• Participant has ventriculoperitoneal shunt
• Participant has a coagulopathy or bleeding disorder
• Participant is HIV+ (human immunodeficiency virus) or has acute CMV (cytomegalovirus)infection
• Participant has any uncontrolled illness, including ongoing or active infection;participant has known active hepatitis B or C infection; participants with any signsor symptoms of active infection, positive blood cultures or radiological evidence ofinfections
• Participant has an autoimmune disease that requires constant treatment
• Participant has another active malignancy
• Participant is unable to undergo a brain magnetic resonance imaging (MRI)
• Participant is pregnant or breast feeding